What is Hemogenyx Pharmaceuticals Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hemogenyx Pharmaceuticals's Enterprise Value is €26.34 Mil.
Hemogenyx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.43 Mil. Therefore, Hemogenyx Pharmaceuticals's EV-to-EBIT ratio for today is -3.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hemogenyx Pharmaceuticals's Enterprise Value
For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemogenyx Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Hemogenyx Pharmaceuticals's Enterprise Value falls into.
Hemogenyx Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Hemogenyx Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemogenyx Pharmaceuticals (STU:5HU) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Hemogenyx Pharmaceuticals's EV-to-EBIT for today is
Hemogenyx Pharmaceuticals's current Enterprise Value is €26.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hemogenyx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.43 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Hemogenyx Pharmaceuticals's EV-to-EBITDA for today is:
Hemogenyx Pharmaceuticals's current Enterprise Value is €26.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hemogenyx Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-6.67 Mil.
Hemogenyx Pharmaceuticals's current Enterprise Value is €26.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hemogenyx Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemogenyx Pharmaceuticals Enterprise Value Related Terms
Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Hemogenyx Pharmaceuticals (STU:5HU) Business Description
Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:5HU has been successfully added to your 